Researchers at the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore have uncovered a previously unknown mechanism that helps cancer cells avoid immune detection, according to a study published in Science Immunology. The team identified the RNA helicase DDX6 as a key suppressor of innate immune signalling in tumour cells and say that targeting it could improve the effectiveness of cancer immunotherapies.
How tumours hide
Our innate immune system recognises a variety of danger signals. One of these is double‑stranded RNA (dsRNA), molecules that can resemble viral RNA and trigger antiviral pathways within cells. Tumours frequently damp down these alarm signals so they do not provoke an immune attack. Prior research had shown that the RNA‑editing enzyme ADAR1 helps regulate cellular responses to dsRNA. The new work adds DDX6 to that regulatory network.
Led by Associate Professor Polly Chen, deputy director and principal investigator at CSI Singapore, the research team found that DDX6 partners with ADAR1 to reduce the presence or signalling of endogenous dsRNA, thereby lowering immune activation against cancer cells. In effect, DDX6 functions as a molecular "cloak" that helps tumours remain under the immune system's radar.
"Cancer cells are remarkably good at hiding from the immune system. Our study uncovered a previously unknown mechanism that helps them stay hidden. By targeting DDX6, we may be able to remove this 'cloak' and enable the immune system to recognize and attack cancer more effectively."
Therapeutic implications
The authors suggest that inhibiting DDX6 could make tumours more visible to the immune system and thereby augment existing or future immunotherapies. Immunotherapy—treatments that boost the body's immune response against cancer—has transformed outcomes for several malignancies, but many tumours remain resistant. Understanding how cancer cells suppress innate immune signalling is therefore central to expanding the reach of these therapies.
Key points emerging from the paper include:
- DDX6 acts as a suppressor of dsRNA sensing in cancer cells.
- DDX6 and ADAR1 cooperate to reduce immune activation triggered by endogenous dsRNA.
- Targeting DDX6 could render tumours more detectable to the immune system and improve responses to immunotherapy.
Context and caveats
The findings deepen molecular understanding of innate immune regulation in tumours but do not by themselves constitute a new treatment. Translating this discovery into therapies will require development of safe and specific DDX6 inhibitors, evaluation in animal models and carefully designed clinical trials to assess efficacy and safety. It is also necessary to establish whether DDX6 inhibition would selectively unmask cancer cells without provoking harmful systemic inflammation or autoimmunity.
The study was published in a peer‑reviewed journal and originates from a recognised research centre, lending credibility to the results. However, as with all laboratory discoveries, further replication and extension by independent groups will be essential before clinical application.
| Protein | Reported role |
|---|---|
| DDX6 | RNA helicase that suppresses dsRNA sensing, helping tumours evade immune detection |
| ADAR1 | RNA‑editing enzyme that modulates cellular responses to dsRNA |
For clinicians and researchers, the discovery opens a potential new avenue to sensitize tumours to immune attack. For patients and the public, it underscores why basic molecular research remains critical: by revealing the mechanisms tumours use to survive, it points to strategies that could one day translate into more effective and durable therapies.
Further work will need to determine the breadth of tumours that rely on the DDX6‑ADAR1 axis, whether particular cancer types are more susceptible, and how DDX6 inhibitors might be combined safely with current immunotherapies.
